Results 191 to 200 of about 3,067,072 (318)
JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology. [PDF]
Foggi G +7 more
europepmc +1 more source
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu +10 more
wiley +1 more source
Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis. [PDF]
Alhalabi M, Alshiekh HA.
europepmc +1 more source
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley +1 more source
Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy. [PDF]
Zak J, Teijaro JR.
europepmc +1 more source
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak +10 more
wiley +1 more source
Clinical updates of JAK inhibitors in cutaneous granulomatous diseases. [PDF]
Gu J +8 more
europepmc +1 more source
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Salvage therapy with JAK inhibitors in refractory Takayasu arteritis: a multicentre experience. [PDF]
Mekinian A +22 more
europepmc +1 more source
The emerging safety profile of JAK inhibitors in rheumatic disease
K. Winthrop
semanticscholar +1 more source

